这项研究的目的是评估六种程序性细胞死亡-1抑制剂(nivolumab,pembrolizumab,sintilmab,tislelizumab,托里帕利玛,和camrelizumab)已被用作中国晚期非小细胞肺癌(NSCLC)患者的一线治疗,尚不清楚。我们通过观察患者的生存数据来确定疗效的差异,目的是为未来的治疗方案提供信息。2015年6月至2023年4月的回顾性数据分析包括6组913例患者:nivolumab(123%,13.5%),pembrolizumab(421%,46.1%),辛替利玛(239%,26.1%),tislelizumab(64%,7.0%),托里帕利马(39%,4.3%),和camrelizumab(27%,3.0%)。每组的中位无进展生存期(PFS)分别为16.0、16.1、18.4、16.9、23.7和12.8个月,中位总生存期(OS)为33.7、36.1、32.5,未达到,nivolumab的30.9和46.0个月,sintilmab,pembrolizumab,tislelizumab,托里帕利玛,和camrelizumab组,分别。虽然两组之间的客观反应率存在差异(p<0.05),PFS和OS差异均无统计学意义(均p>0.05)。研究结果表明,这些PD-1抑制剂对NSCLC治疗的疗效相当。强调他们的集体适用性和帮助治疗决定。
The purpose of this study was to assess the comparative efficacy of six programmed cell death-1 inhibitors (nivolumab, pembrolizumab, sintilimab, tislelizumab, toripalimab, and camrelizumab) that have been used as first-line therapy for Chinese patients with advanced non-small cell lung cancer (NSCLC), which remains unclear. We determined the differences in efficacy by observing patient survival data, with the goal of informing future treatment options. Retrospective data analysis from June 2015 to April 2023 included 913 patients across six groups: nivolumab (123%, 13.5%), pembrolizumab (421%, 46.1%), sintilimab (239%, 26.1%), tislelizumab (64%, 7.0%), toripalimab (39%, 4.3%), and camrelizumab (27%, 3.0%). The median progression-free survival (PFS) for each group was 16.0, 16.1, 18.4, 16.9, 23.7, and 12.8 months, and the median overall survival (OS) was 33.7, 36.1, 32.5, not reached, 30.9 and 46.0 months for the nivolumab, sintilimab, pembrolizumab, tislelizumab, toripalimab, and camrelizumab groups, respectively. While differences existed in the objective response rates among groups (p < 0.05), there were no significant differences (all p > 0.05) in PFS or OS. The findings suggest comparable efficacy among these PD-1 inhibitors for NSCLC treatment, underscoring their collective suitability and aiding treatment decisions.